2013 China Human Immunoglobulin (pH4) for Intravenous Injection Industry Research Report


Dublin, Nov. 13, 2013 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/h7pjxj/2013_china_human) has announced the addition of the "2013 China Human Immunoglobulin (pH4) for Intravenous Injection Industry Research Report" report to their offering.

This 2013 research report is a professional and in-depth research report on the Chinese Human Immunoglobulin (pH4) for Intravenous Injection industry. This report firstly discusses the definition, classification, industry chain and other related information of this industry.

It then reviews manufacturing technology, product specifications and summary statistics of 25 major Chinese manufacturers 2010-2016 giving details on capacity, production, supply, demand, shortage, selling price, cost, gross margin, production value and market share.

In the end, this report discusses the 200K Bottles/year project feasibility analysis and investment return analysis, and gives related research conclusions and development trend analysis of the Chinese Human Immunoglobulin (pH4) for Intravenous Injection industry.
 

Key Topics Covered:

Chapter One Human Immunoglobulin (pH4) for Intravenous Injection Industry Overview

Chapter Two Human Immunoglobulin (pH4) for Intravenous Injection Manufacturing Process and Cost Analysis

Chapter Three Human Immunoglobulin (pH4) for Intravenous Injection Production Supply Sales Demand Market Status and Forecast

Chapter Four Human Immunoglobulin (pH4) for Intravenous Injection Key Manufacturers Analysis

Chapter Five Human Immunoglobulin (pH4) for Intravenous Injection Project Investment Feasibility Analysis

Chapter Six Human Immunoglobulin (pH4) for Intravenous Injection Industry Research Conclusions


Companies Mentioned

  • Banghe Pharmaceutical Co.,Ltd.
  • Boya Biological (300294)
  • CTBB
  • Greencross(China)
  • Guangdong Shuanglin Bio-pharmacy Co.,Ltd.
  • Guangdong Weilun Biological Pharmaceutical Co.,Ltd.
  • Guizhou Taibang Biological Products Co.,Ltd.
  • Guizhou Zhongtai Biological S&T Co.,Ltd.
  • Haikang Biological Products Co.,Ltd.
  • Hualan Bio (002007)
  • Hunan Unisplendour Guhan Nanyue-pharmaceutical Co.,Ltd. (000590)
  • Lanzhou Institute of Biological Products Co.,Ltd.
  • PAFC
  • Ronsen Pharmaceutical
  • Shanghai Institute of Biological Products Co.,Ltd.
  • Shanghai RAAS (002252)
  • Shanghai Xinxing Medicine Co.,Ltd.
  • Shanxi Kangbao Biological Product Co.,Ltd.
  • Shenzhen Weiwuguangming Biological Products Co.,Ltd.
  • Sichuan Yuanda Shuyang Pharmaceutical Co.,Ltd.
  • Tonrol Pharmaceutical
  • Walvax Biotechnology Co.,Ltd. (300142) (Hebei Daan)
  • Wuhan Institute of Biological Products Co.,Ltd.
  • Wuhan Zhongyuan Ruide Biological Products Co.,Ltd.
  • Xi'an Huitian Blood Products Co.,Ltd.

For more information visit http://www.researchandmarkets.com/research/h7pjxj/2013_china_human

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals